<DOC>
	<DOCNO>NCT03006991</DOCNO>
	<brief_summary>This study integrate Pharmacogenomics Pharmacometrics , explore effective concentration MTXPGn JIA pediatric patient , set Population Pharmacokinetics model provide reference individual administration JIA pediatric patient .</brief_summary>
	<brief_title>Study Methotrexate Given Juvenile Idiopathic Arthritis Patients Based Pharmacogenomics Pharmacometrics</brief_title>
	<detailed_description>In order find `` The critical reason individual variance MTX JIA pediatric patient quantize influence factor '' , base early research , study integrate Pharmacogenomics Pharmacometrics , explore effective concentration MTXPGn JIA pediatric patient , set Population Pharmacokinetics model provide reference individual administration JIA pediatric patient .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Pediatric patient Juvenile Idiopathic Arthritis 7.510mg/m2 per week per dose methotrexate patient treated methotrexate least 3 month cotreated drug interact methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>methotrexate , Juvenile Idiopathic Arthritis</keyword>
</DOC>